MX2014006182A - Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr. - Google Patents

Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr.

Info

Publication number
MX2014006182A
MX2014006182A MX2014006182A MX2014006182A MX2014006182A MX 2014006182 A MX2014006182 A MX 2014006182A MX 2014006182 A MX2014006182 A MX 2014006182A MX 2014006182 A MX2014006182 A MX 2014006182A MX 2014006182 A MX2014006182 A MX 2014006182A
Authority
MX
Mexico
Prior art keywords
egfr inhibitor
treatment
patient
predicting responsiveness
egfr
Prior art date
Application number
MX2014006182A
Other languages
English (en)
Inventor
Thomas Rio Frio
Pierre Laurent-Puig
Sandrine Imbeaud
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of MX2014006182A publication Critical patent/MX2014006182A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un método para predecir si es probable que un paciente con un cáncer responda a un inhibidor de receptor del factor de crecimiento epidérmico (EGFR por sus siglas en inglés), el método comprende determinar el nivel de expresión de HSA-miR-31-3p miARN en una muestra del paciente. La invención también se refiere a usos terapéuticos de un inhibidor de EGFR en un paciente que se asume responde al inhibidor de EGFR.
MX2014006182A 2011-11-25 2012-11-23 Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr. MX2014006182A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11306568 2011-11-25
EP12306042 2012-08-31
PCT/EP2012/073535 WO2013076282A1 (en) 2011-11-25 2012-11-23 A method for predicting responsiveness to a treatment with an egfr inhibitor

Publications (1)

Publication Number Publication Date
MX2014006182A true MX2014006182A (es) 2014-12-08

Family

ID=47297187

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006182A MX2014006182A (es) 2011-11-25 2012-11-23 Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr.

Country Status (10)

Country Link
US (1) US10400284B2 (es)
EP (1) EP2783017B1 (es)
JP (1) JP6342329B2 (es)
KR (1) KR20140104419A (es)
CN (1) CN104160038B (es)
AU (1) AU2012342397B2 (es)
BR (1) BR112014012495A2 (es)
CA (1) CA2856594A1 (es)
MX (1) MX2014006182A (es)
WO (1) WO2013076282A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3074530A1 (en) * 2013-11-26 2016-10-05 Integragen A method for predicting responsiveness to a treatment with an egfr inhibitor
KR101622454B1 (ko) 2014-03-04 2016-05-18 연세대학교 산학협력단 Egfr 티로신 키나아제 억제제에 대한 항암 치료 반응 예측 마커
ES2823756T3 (es) * 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
EP3000895A1 (en) 2014-09-26 2016-03-30 Integragen A method for predicting responsiveness to a treatment with an EGFR inhibitor
WO2017014694A1 (en) * 2015-07-23 2017-01-26 National University Of Singapore Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment
KR102367595B1 (ko) * 2016-04-28 2022-02-25 덴카 주식회사 상피성 세포 성장 인자 수용체 저해제에 대한 암세포의 내성을 판정하는 방법
CN115943306A (zh) * 2019-03-29 2023-04-07 乐天医药生技股份有限公司 用于光免疫疗法的方法和相关生物标志物
KR102251864B1 (ko) * 2019-10-18 2021-05-14 지니너스 주식회사 miR-320c를 유효성분으로 포함하는 백금계 항암제에 대한 삼중음성유방암 환자의 약물 반응성 예측용 바이오마커 조성물
CN111798918A (zh) * 2020-05-28 2020-10-20 中山大学孙逸仙纪念医院 一种免疫治疗疗效预测的血肿瘤突变算法及其构建方法
CN111863159B (zh) * 2020-06-01 2022-02-25 中山大学孙逸仙纪念医院 一种肿瘤免疫治疗疗效预测的列线图模型的建立方法
WO2023165494A1 (en) * 2022-03-01 2023-09-07 Crown Bioscience (Suzhou) Inc. Methods for determining cetuximab sensitivity in cancer patients

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2439402A1 (en) 2001-03-02 2002-09-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pcr method
JP2011500086A (ja) * 2007-10-22 2011-01-06 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
WO2009080437A1 (en) * 2007-12-21 2009-07-02 Exiqon A/S Micro-rna based drug resistance analysis method
WO2010015538A2 (en) * 2008-08-05 2010-02-11 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
US20120095030A1 (en) 2009-04-17 2012-04-19 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors
JP2013511559A (ja) * 2009-11-24 2013-04-04 ザ ユニバーシティ オブ ウェスタン オーストラリア 上皮成長因子受容体リガンドのモジュレーション
CA2800557A1 (en) * 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy

Also Published As

Publication number Publication date
WO2013076282A1 (en) 2013-05-30
US10400284B2 (en) 2019-09-03
JP2014533960A (ja) 2014-12-18
EP2783017B1 (en) 2018-12-26
BR112014012495A2 (pt) 2017-06-06
US20140370029A1 (en) 2014-12-18
JP6342329B2 (ja) 2018-06-13
AU2012342397B2 (en) 2018-04-05
AU2012342397A1 (en) 2014-06-12
KR20140104419A (ko) 2014-08-28
CN104160038B (zh) 2018-06-12
CA2856594A1 (en) 2013-05-30
EP2783017A1 (en) 2014-10-01
CN104160038A (zh) 2014-11-19

Similar Documents

Publication Publication Date Title
MX2014006182A (es) Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr.
LTPA2019503I1 (lt) Modifikuotų T ląstelių, turinčių chimerinų antigeno receptorių, panaudojimas vėžio gydymui
WO2013009655A3 (en) Uses of labeled hsp90 inhibitors
IL233019A0 (en) System and method for locating sources of biological arrhythmias
EP2770090A4 (en) METHOD FOR PRODUCING A NUCLEIC ACID LIBRARY AND USES THEREOF AND KITS THEREFOR
IN2012DN02485A (es)
PT2683384E (pt) Métodos de tratamento de cancro utilizando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona
IN2014DN04645A (es)
MX358541B (es) Metodos para predecir el riesgo de desarrollar hipertension.
WO2012106718A3 (en) Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
EA201490265A1 (ru) Ингибиторы тирозинкиназы брутона
WO2011146568A8 (en) Predicting response to a her inhibitor
EP2788773A4 (en) DEVICE, SYSTEM AND METHOD FOR IDENTIFYING CIRCULATING TUMOR CELLS
MX2015018051A (es) Expresión génica basada en arnm para personalizar la terapia del cáncer al paciente con un antagonista de mdm2.
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
WO2013040436A3 (en) Esx-mediated transcription modulators and related methods
EA201590773A1 (ru) Способ диагностики для прогнозирования ответа на ингибитор фактора некроза опухоли альфа (tnf альфа)
MX354270B (es) Uso de un anticuerpo antiesclerostina en el tratamiento de la pérdida ósea alveolar. .
PH12013502530A1 (en) Glioblastoma inhibiting compounds and their use
EP2568459A4 (en) TRAFFIC CONTROL SYSTEM AND METHOD
IL232493A0 (en) A method for quantifying cancer treatment
MX2016006782A (es) Un metodo para predecir la capacidad de respuesta a un tratamiento con un inhibidor del egfr.
PL2678443T3 (pl) Sposób ilościowego określania ludzkiego DNA przy użyciu kontroli wewnętrznej
GB201312965D0 (en) Stem cell factor inhibitor
EA201500670A1 (ru) Egfr-направленная терапия неврологических нарушений и боли